The ARTEMIS trial identifies immune activation as a key predictor of neoadjuvant chemotherapy response in triple-negative breast cancer

Abstract Background Selecting treatments for triple-negative breast cancer (TNBC) remains challenging due to its high molecular and phenotypic heterogeneity. To maximize response rates, nearly all patients are treated with an aggressive combination of chemo-immunotherapy. However, since half of pati...

Descripció completa

Dades bibliogràfiques

Autors principals:	Sahil Seth, Clinton Yam, Lei Huo, Bora Lim, Amanda L. Rinkenbaugh, Jason B. White, Elizabeth E. Ravenberg, Xingzhi Song, Jennifer K. Litton, Debu Tripathy, Vicente Valero, Senthil Damodaran, Banu Arun, Naoto T. Ueno, Anthony Lucci, Alastair M. Thompson, Elizabeth A. Mittendorf, Gaiane M. Rauch, Beatriz Adrada, Rosalind P. Candelaria, Qingqing Ding, Reid T. Powell, Nour K. Abuhadra, Jianhua Zhang, Andrew Futreal, Giulio F. Draetta, Helen Piwnica-Worms, William F. Symmans, Jeffrey T. Chang, Stacy L. Moulder
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2026-05-01
Col·lecció:	Breast Cancer Research
Matèries:	Triple-negative breast cancer Chemoresistance Transcriptomics
Accés en línia:	https://doi.org/10.1186/s13058-026-02290-z
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!